Severity of coeliac disease and clinical management study when using a CYP3A4 metabolised medication: a phase I pharmacokinetic study

OBJECTIVE: Severity of coeliac disease depends in part on the extent of small intestinal mucosa injury. Patients with the most abnormal pathology have loss of duodenal villi CYP3A4, a drug-metabolising enzyme that inactivates many drugs. These patients are hypothesised to have greater systemic conce...

Descripción completa

Detalles Bibliográficos
Autores principales: Chretien, Marc L, Bailey, David G, Asher, Linda, Parfitt, Jeremy, Driman, David, Gregor, Jamie, Dresser, George K
Formato: Online Artículo Texto
Lenguaje:English
Publicado: BMJ Publishing Group 2020
Materias:
Pharmacology and Therapeutics
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC7059485/
https://www.ncbi.nlm.nih.gov/pubmed/32139488
http://dx.doi.org/10.1136/bmjopen-2019-034086

Internet

https://www.ncbi.nlm.nih.gov/pmc/articles/PMC7059485/
https://www.ncbi.nlm.nih.gov/pubmed/32139488
http://dx.doi.org/10.1136/bmjopen-2019-034086

Ejemplares similares